Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion
Alireza Faridar, Aaron D. Thome, Weihua Zhao, et al.
Brain Communications (2020) Vol. 2, Iss. 2
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Neuroinflammation in Alzheimer disease
Wiesje M. van der Flier, Wiesje M. van der Flier, Frank Jessen, et al.
Nature reviews. Immunology (2024)
Closed Access | Times Cited: 16
CD4+ effector T cells accelerate Alzheimer’s disease in mice
Jatin Machhi, Pravin Yeapuri, Yaman Lu, et al.
Journal of Neuroinflammation (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 93
Neuroimmune contributions to Alzheimer’s disease: a focus on human data
Verena Haage, Philip L. De Jager
Molecular Psychiatry (2022) Vol. 27, Iss. 8, pp. 3164-3181
Open Access | Times Cited: 43
Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimer's disease
Hyejin Yang, Seon‐Young Park, Hyunjung Baek, et al.
Theranostics (2022) Vol. 12, Iss. 18, pp. 7668-7680
Open Access | Times Cited: 39
Regulatory T cells in peripheral tissue tolerance and diseases
Nardos Tesfaye Cheru, David A. Hafler, Tomokazu S. Sumida
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 28
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
Daniela Melchiorri, Sara Merlo, Benjamin Micallef, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 26
Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice
Pravin Yeapuri, Jatin Machhi, Yaman Lu, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 26
N-acetylneuraminic acid links immune exhaustion and accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model
Stefano Suzzi, Tommaso Croese, Adi Ravid, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 24
T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease
Junjian Zeng, Zhiqiang Liao, Hanqin Yang, et al.
Neurobiology of Disease (2024) Vol. 193, pp. 106461-106461
Open Access | Times Cited: 13
The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer’s disease
Marie Sarazin, Julien Lagarde, I. Haddad, et al.
Nature Aging (2024) Vol. 4, Iss. 6, pp. 761-770
Closed Access | Times Cited: 11
Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol
Jonas E. Svensson, Martin Bolin, Daniel E. Thor, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease
Barbara Rossi, Bruno Santos-Lima, Eleonora Terrabuio, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 52
Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease
Aaron D. Thome, Farah Atassi, Jinghong Wang, et al.
npj Parkinson s Disease (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 51
The Influence of Virus Infection on Microglia and Accelerated Brain Aging
Luis Filgueira, Alexey Larionov, Nils Lannes
Cells (2021) Vol. 10, Iss. 7, pp. 1836-1836
Open Access | Times Cited: 47
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis
Jason R. Thonhoff, James Berry, Eric A. Macklin, et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 35
Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease
Alireza Faridar, Matthew Vasquez, Aaron D. Thome, et al.
Acta Neuropathologica Communications (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 34
Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases
Bao‐Guo Xiao, Cun‐Gen Ma, Qing Wang, et al.
Neural Regeneration Research (2022) Vol. 17, Iss. 12, pp. 2623-2623
Open Access | Times Cited: 32
The potential for treg-enhancing therapies in nervous system pathologies
Katherine E. Olson, R. Lee Mosley, Howard E. Gendelman
Clinical & Experimental Immunology (2022) Vol. 211, Iss. 2, pp. 108-121
Open Access | Times Cited: 30
Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease
Katherine E. Olson, Krista L. Namminga, Yaman Lu, et al.
EBioMedicine (2021) Vol. 67, pp. 103380-103380
Open Access | Times Cited: 39
Interleukin-4 receptor signaling modulates neuronal network activity
Nicholas Hanuscheck, Carine Thalman, Micaela Domingues, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 6
Open Access | Times Cited: 27
Crossing borders in Alzheimer’s disease: A T cell’s perspective
Lynn van Olst, Loet Coenen, Juliana M. Nieuwland, et al.
Advanced Drug Delivery Reviews (2022) Vol. 188, pp. 114398-114398
Open Access | Times Cited: 24
Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy
Si-Jia Hou, Sheng‐Xiao Zhang, Li Yang, et al.
Clinical Interventions in Aging (2023) Vol. Volume 18, pp. 1629-1639
Open Access | Times Cited: 15
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Alireza Faridar, Abdulmunaim M. Eid, Aaron D. Thome, et al.
Translational Neurodegeneration (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
Valerie Saetzler, Tobias Riët, Andrea Schienke, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2115-2115
Open Access | Times Cited: 13
Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond
Giacomo Tondo, Fabiola De Marchi, Francesca Bonardi, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3098-3098
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top